<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079767</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000666229</org_study_id>
    <secondary_id>FFCD-0903</secondary_id>
    <secondary_id>EUDRACT-2009-014443-36</secondary_id>
    <secondary_id>EU-21004</secondary_id>
    <nct_id>NCT01079767</nct_id>
  </id_info>
  <brief_title>Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis</brief_title>
  <official_title>Advanced Hepatocellular Carcinoma on Child B Cirrhosis: Tolerance and Efficacy of Torisel® (Temsirolimus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well temsirolimus works in treating patients&#xD;
      with advanced liver cancer and cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the 3-month disease-control rate according to RECIST criteria in patients&#xD;
           with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the 3-month objective response rate according to RECIST criteria in these&#xD;
           patients.&#xD;
&#xD;
        -  To determine the 1-month metabolic response rate on PET/CT scan in these patients.&#xD;
&#xD;
        -  To determine the 1-month perfusion response rate on hepatic perfusion CT scan in these&#xD;
           patients.&#xD;
&#xD;
        -  To determine the time to progression in patients treated with this drug.&#xD;
&#xD;
        -  To determine the progression-free survival of patients treated with this drug.&#xD;
&#xD;
        -  To determine the overall survival of patients treated with this drug.&#xD;
&#xD;
        -  To assess quality of life according to QLQ-C30 and QLQ-HCC18 questionnaires.&#xD;
&#xD;
        -  To determine the clinical and biological tolerance of this drug in these patients.&#xD;
&#xD;
        -  To determine the rate of m-TOR pathway activation and VEGF level.&#xD;
&#xD;
        -  To evaluate the pharmacokinetics of this drug in select patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive temsirolimus IV over 30-60 minutes on day 1. Treatment repeats once a week&#xD;
      in the absence of disease progression or unacceptable toxicity. Patients also undergo&#xD;
      fludeoxyglucose F 18 (FDG) positron emission tomography/computed tomography (PET/CT) scan and&#xD;
      perfusion CT scan of the liver at baseline and periodically during study treatment.&#xD;
&#xD;
      Patients complete quality of life questionnaires (QLC-C30 and QLQ-HCC18) periodically. Some&#xD;
      patients undergo blood and tissue sample collection periodically for pharmacological and&#xD;
      laboratory studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed for up to 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study treminated early according to DSMB recommendantions&#xD;
  </why_stopped>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-month disease-control rate according to RECIST criteria</measure>
    <time_frame>2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-month objective response rate according to RECIST criteria</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Temsirolimus</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Temsirolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <arm_group_label>Temsirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of hepatocellular carcinoma (HCC) according to the European Association for&#xD;
             the Study of the Liver (EASL) criteria&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
               -  Must be morphologically evaluable&#xD;
&#xD;
          -  HCC not accessible to other treatment (e.g., surgery, radiofrequency, or&#xD;
             chemoembolization) and can not benefit from antiangiogenic therapy&#xD;
&#xD;
          -  CLIP score ≤ 3 (except for patients with tumors invading more than 50% of tumor&#xD;
             volume)&#xD;
&#xD;
          -  Child-Pugh cirrhosis score between B7 and B9, meeting the following criteria:&#xD;
&#xD;
               -  Diagnosed clinically, biologically (e.g., prothrombin time, platelets, or&#xD;
                  albumin), endoscopically (signs of portal hypertension) and morphologically&#xD;
                  (dysmorphic liver on ultrasound or CT scan), or by liver biopsy&#xD;
&#xD;
          -  Not a candidate for transplantation and has not received a liver transplant&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3&#xD;
&#xD;
          -  Neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  GFR ≥ 30 mL/min&#xD;
&#xD;
          -  Serum cholesterol ≤ 350 mg/dL&#xD;
&#xD;
          -  Triglycerides ≤ 300 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for more than 2 months&#xD;
             after completion of study therapy&#xD;
&#xD;
          -  No history of other cancer on treatment&#xD;
&#xD;
          -  No cardiopulmonary disease impairment, including a history of stable or unstable&#xD;
             angina or myocardial infarction&#xD;
&#xD;
          -  No active infection except for viral hepatitis&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior inhibitors or inducers of P-glycoprotein, CYP3A4, or&#xD;
             CYP3A5&#xD;
&#xD;
          -  At least 4 weeks since prior surgery, radiotherapy (except radiotherapy to the bone),&#xD;
             transarterial chemoembolization, immunotherapy, or other investigational drug for HCC&#xD;
&#xD;
          -  At least 6 months since prior chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Decaens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Henri Mondor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Duvoux</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Henri Mondor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

